Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-04-2566PMID 16115936
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

  2003cited by this paper
• Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.

  2003cited by this paper
• Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.

  2003cited by this paper
• Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.

  2003cited by this paper
• Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells.

  2003cited by this paper
• Protein Kinase C-dependent Activation of the Tumor Necrosis Factor Receptor-mediated Extrinsic Cell Death Pathway Underlies Enhanced Apoptosis in Human Myeloid Leukemia Cells Exposed to Bryostatin 1 and Flavopiridol1

  2003cited by this paper
• Flavopiridol Inversely Affects p21WAF1/CIP1 and p53 and Protects p21-Sensitive Cells from Paclitaxel

  2002cited by this paper
• Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)

  2002cited by this paper
• A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4.

  2002cited by this paper
• Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.

  2002cited by this paper
• Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo *

  2001cited by this paper
• Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.

  2001cited by this paper
• Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.

  2001cited by this paper
• Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.

  2000cited by this paper
• Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.

  2000cited by this paper
• Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.

  2000cited by this paper
• Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication*

  2000cited by this paper
• Flavopiridol binds to duplex DNA.

  2000cited by this paper
• Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

  1998cited by this paper
• Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

  1998cited by this paper
• Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.

  1998cited by this paper
• Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.

  1998cited by this paper
• Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.

  1998cited by this paper
• Phase Ib trial of bryostatin 1 in patients with refractory malignancies.

  1998cited by this paper
• Cell cycle‐independent induction of apoptosis by the anti‐tumor drug flavopiridol in endothelial cells

  1998cited by this paper
• The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.

  1997cited by this paper
• Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.

  1997cited by this paper
• Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.

  1997cited by this paper
• Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells.

  1996cited by this paper
• Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.

  1996cited by this paper
• Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

  1996cited by this paper
• Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

  1996cited by this paper
• Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

  1994cited by this paper
• Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.

  1993cited by this paper
• Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.

  1992cited by this paper
• Antineoplastic Agents: the Importance of Sequence of Administration'

  year unknowncited by this paper

• Research progress of flavonoids targeting estrogen receptor in the treatment of breast cancer.

  2025cites this paper
• Seize the engine: Emerging cell cycle targets in breast cancer

  2024cites this paper
• Flavonoids for the treatment of breast cancer, present status and future prospective.

  2022cites this paper
• Triazole based isatin derivatives as potential inhibitor of key cancer promoting kinases- insight from electronic structure, docking and molecular dynamics simulations.

  2021cites this paper
• Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

  2020influential citation
• Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma

  2020cites this paper
• Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.

  2019cites this paper
• Flavopiridol Induces Apoptosis via Mitochondrial Pathway in B16F10 Murine Melanoma Cells and a Subcutaneous Melanoma Tumor Model.

  2016cites this paper
• Cyclin D1 is a strong prognostic factor for survival in pancreatic cancer: Analysis of CD G870A polymorphism, FISH and immunohistochemistry

  2015cites this paper
• Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.

  2015cites this paper
• Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer

  2015cites this paper
• CDK4 inhibitors an emerging strategy for the treatment of melanoma.

  2015cites this paper
• CDK Inhibitors in Cancer Research and Clinical Therapy

  2014cites this paper
• Targetting Cdks in Cancer: An Overview and New Insights

  2014cites this paper
• Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies

  2014cites this paper
• Novel Therapeutic Strategies for Pancreatic Cancer

  2014cites this paper
• Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.

  2013cites this paper
• Effects of alvocidib and carboplatin on ovarian cancer cells in vitro.

  2013cites this paper
• Identification de nouvelles structures inhibitrices de kinases : conception synthèse et évaluation biologique

  2013cites this paper
• Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program

  2012cites this paper
• Clinical Pharmacokinetics of Flavonoids

  2012cites this paper
• A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

  2012cites this paper
• Anthranilamide–Pyrazolo[1,5‐a]pyrimidine Conjugates as p53 Activators in Cervical Cancer Cells

  2012cites this paper
• Cyclin dependent kinases in cancer

  2012cites this paper
• Off‐target immune cell toxicity caused by AG‐012986, a pan‐CDK inhibitor, is associated with inhibition of p38 MAPK phosphorylation

  2012cites this paper
• Cyclin-Dependent Kinases (Cdk) as Targets for Cancer Therapy and Imaging

  2011cites this paper
• Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.

  2011cites this paper
• The CDK inhibitors in cancer research and therapy

  2011cites this paper
• Organometallic 3-(1H-Benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as Potential Anticancer Agents

  2011cites this paper
• Cyclin dependent kinase 1 inhibitors: a review of recent progress.

  2011cites this paper
• Targeting Mcl-1 for the therapy of cancer

  2011cites this paper
• Radioprotectors and Chemoprotectors in the Management of Lung Cancer

  2011cites this paper
• A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model.

  2010cites this paper
• Cell cycle as a target of antineoplastic drugs.

  2010cites this paper
• Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.

  2010cites this paper
• Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors

  2010cites this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

  2010cites this paper
• Targeting Protein Kinases for Cancer Therapy

  2010influential citation
• Cell cycle as a target of antineoplastic drugs.

  2010cites this paper
• Halogen atoms in the modern medicinal chemistry: hints for the drug design.

  2010cites this paper
• Targeting Cyclin-Dependent Kinases for Cancer Therapy

  2010cites this paper
• A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

  2010cites this paper
• Cyclin-dependent kinase inhibitors as potential targeted anticancer agents

  2009cites this paper
• Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage

  2009cites this paper
• Development of cell-cycle inhibitors for cancer therapy

  2009cites this paper
• SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

  2009cites this paper
• Influence of aspirin and cigarette smoke extract on the expression of cyclin D1 and effects of cell cycle in esophageal squamous cell carcinoma cell line.

  2009cites this paper
• Safety, pharmacokinetics and pharmacodynamics of targeted anti-cancer drugs

  2009cites this paper
• Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.

  2008cites this paper
• CDK Inhibitors as Anticancer Agents

  2008cites this paper
• Molecular-targeted therapies: lessons from years of clinical development.

  2008cites this paper
• New combination therapies with cell-cycle agents.

  2008cites this paper
• Structure-guided discovery of cyclin-dependent kinase inhibitors.

  2008cites this paper
• Prognostication in esophageal cancer

  2008cites this paper
• Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.

  2008cites this paper
• Turning the gene tap off; implications of regulating gene expression for cancer therapeutics

  2008cites this paper
• Phase IDose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced

  2007cites this paper
• Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer.

  2007cites this paper
• Targeting cell cycle kinases and kinesins in anticancer drug development

  2007cites this paper
• Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer

  2007cites this paper
• Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors

  2007cites this paper
• Targeted therapies in lung cancer.

  2007cites this paper
• Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.

  2007cites this paper
• Development and validation of a phosphorylated SMAD ex vivo stimulation assay

  2007cites this paper
• Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction

  2007cites this paper
• Rational Drug Design of Small Molecule Anticancer Agents: Early Clinical Development

  2007cites this paper
• Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex

  2007cites this paper
• Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.

  2007cites this paper
• Zebrafish as a Model System to Screen Radiation Modifiers

  2007cites this paper
• P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents

  2007cites this paper
• Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos.

  2006cites this paper
• Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects.

  2006cites this paper
• Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer

  2006cites this paper
• Cyclin-Dependent Kinase Inhibitors and Combination Therapy: Experimental and Clinical Status

  2006cites this paper